298 related articles for article (PubMed ID: 29202466)
1. Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.
Zhao B; Mei Y; Cao L; Zhang J; Sumagin R; Yang J; Gao J; Schipma MJ; Wang Y; Thorsheim C; Zhao L; Stalker T; Stein B; Wen QJ; Crispino JD; Abrams CS; Ji P
J Clin Invest; 2018 Jan; 128(1):125-140. PubMed ID: 29202466
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
3. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
4. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
[TBL] [Abstract][Full Text] [Related]
5. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
7. Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.
Shepherd MS; Li J; Wilson NK; Oedekoven CA; Li J; Belmonte M; Fink J; Prick JCM; Pask DC; Hamilton TL; Loeffler D; Rao A; Schröder T; Göttgens B; Green AR; Kent DG
Blood; 2018 Aug; 132(8):791-803. PubMed ID: 29991556
[TBL] [Abstract][Full Text] [Related]
8. Functional interdependence of hematopoietic stem cells and their niche in oncogene promotion of myeloproliferative neoplasms: the 159th biomedical version of "it takes two to tango".
Zhan H; Kaushansky K
Exp Hematol; 2019 Feb; 70():24-30. PubMed ID: 30593829
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
[TBL] [Abstract][Full Text] [Related]
10. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
11. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA
Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689
[TBL] [Abstract][Full Text] [Related]
12. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
13. Concomitant presence of JAK2V617F mutation and BCR‑ABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms (Case report).
Mousinho F; Azevedo AP; Mendes T; Santos PSE; Cerqueira R; Matos S; Santos S; Ramos S; Viana JF; Lima F
Mol Med Rep; 2018 Jul; 18(1):1001-1006. PubMed ID: 29845291
[TBL] [Abstract][Full Text] [Related]
14. Targeting pleckstrin-2/Akt signaling reduces proliferation in myeloproliferative neoplasm models.
Han X; Mei Y; Mishra RK; Bi H; Jain AD; Schiltz GE; Zhao B; Sukhanova M; Wang P; Grigorescu AA; Weber PC; Piwinski JJ; Prado MA; Paulo JA; Stephens L; Anderson KE; Abrams CS; Yang J; Ji P
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36719747
[TBL] [Abstract][Full Text] [Related]
15. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS
Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357
[TBL] [Abstract][Full Text] [Related]
16. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
[TBL] [Abstract][Full Text] [Related]
17. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
[TBL] [Abstract][Full Text] [Related]
18. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
[TBL] [Abstract][Full Text] [Related]
19. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Koppikar P; Abdel-Wahab O; Hedvat C; Marubayashi S; Patel J; Goel A; Kucine N; Gardner JR; Combs AP; Vaddi K; Haley PJ; Burn TC; Rupar M; Bromberg JF; Heaney ML; de Stanchina E; Fridman JS; Levine RL
Blood; 2010 Apr; 115(14):2919-27. PubMed ID: 20154217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
